Top

Published in:

Open Access 01-12-2020 | Obesity | Neurological Update

Emerging themes in idiopathic intracranial hypertension

Authors: Olivia Grech, Susan P. Mollan, Benjamin R. Wakerley, Zerin Alimajstorovic, Gareth G. Lavery, Alexandra J. Sinclair

Published in: Journal of Neurology | Issue 12/2020

Abstract

Purpose

Idiopathic intracranial hypertension (IIH) is a rare disorder characterised by raised intracranial pressure. The underlying pathophysiology is mostly unknown and effective treatment is an unmet clinical need in this disease. This review evaluates key emerging themes regarding disease characteristics, mechanisms contributing to raised intracranial pressure and advances in potential therapeutic targets.

Findings

IIH is becoming more common, with the incidence rising in parallel with the global obesity epidemic. Current medical management remains centred around weight management, which is challenging. Metabolic investigations of patients have identified specific androgen profiles in cerebrospinal fluid (CSF), which suggest an endocrine dysfunction impacting CSF secretion in IIH. Glucagon-like peptide-1 (GLP-1) and 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) have been found to play a role in CSF dynamics in IIH and have formed the basis of the first clinical trials looking at new treatments.

Conclusions

Identification of novel molecular targets thought to underlie IIH pathology is now being translated to clinical trials.

Markey KA, Mollan SP, Jensen RH, Sinclair AJ (2016) Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurol 15(1):78–91PubMed

Mollan SP, Davies B, Silver NC, Shaw S, Mallucci CL, Wakerley BR, Krishnan A, Chavda SV, Ramalingam S, Edwards J et al (2018) Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry 89(10):1088–1100PubMedPubMedCentral

Mollan SP, Aguiar M, Evison F, Frew E, Sinclair AJ (2018) The expanding burden of idiopathic intracranial hypertension. Eye (Lond) 33(3):478–485

McCluskey G, Doherty-Allan R, McCarron P, Loftus AM, McCarron LV, Mulholland D, McVerry F, McCarron MO (2018) Meta-analysis and systematic review of population-based epidemiological studies in idiopathic intracranial hypertension. Eur J Neurol 25(10):1218–1227PubMed

Wall M, Kupersmith MJ, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner JL, Schron EB, McDermott MP et al (2014) The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol 71(6):693–701PubMedPubMedCentral

Mollan SP, Ali F, Hassan-Smith G, Botfield H, Friedman DI, Sinclair AJ (2016) Evolving evidence in adult idiopathic intracranial hypertension: pathophysiology and management. J Neurol Neurosurg Psychiatry 87(9):982–992PubMedPubMedCentral

Mollan SP, Markey KA, Benzimra JD, Jacks A, Matthews TD, Burdon MA, Sinclair AJ (2014) A practical approach to, diagnosis, assessment and management of idiopathic intracranial hypertension. Pract Neurol 14(6):380–390PubMedPubMedCentral

Mulla Y, Markey KA, Woolley RL, Patel S, Mollan SP, Sinclair AJ (2015) Headache determines quality of life in idiopathic intracranial hypertension. J Headache Pain 16:521–521PubMed

Mollan SP, Hoffmann J, Sinclair AJ (2019) Advances in the understanding of headache in idiopathic intracranial hypertension. Curr Opin Neurol 32(1):92–98PubMed

10.

Mollan S, Hemmings K, Herd CP, Denton A, Williamson S, Sinclair AJ (2019) What are the research priorities for idiopathic intracranial hypertension? A priority setting partnership between patients and healthcare professionals. BMJ Open 9(3):e026573PubMedPubMedCentral

11.

Botfield HF, Uldall MS, Westgate CSJ, Mitchell JL, Hagen SM, Gonzalez AM, Hodson DJ, Jensen RH, Sinclair AJ (2017) A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Sci Transl Med 9(404):eaan0972PubMed

12.

Markey K, Mitchell J, Botfield H, Ottridge RS, Matthews T, Krishnan A, Woolley R, Westgate C, Yiangou A, Alimajstorovic Z et al (2020) 11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial. Brain Commun 2(1):fcz050PubMedPubMedCentral

13.

Markey KA, Ottridge R, Mitchell JL, Rick C, Woolley R, Ives N, Nightingale P, Sinclair AJ (2017) Assessing the efficacy and safety of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor (AZD4017) in the idiopathic intracranial hypertension drug trial, IIH:DT: clinical methods and design for a phase II randomized controlled trial. JMIR Res Protoc 6(9):e181PubMedPubMedCentral

14.

IIH Pressure Clinical Trial ISTCRN (12678718). http://www.isrctn.com/ISRCTN12678718. Website last accessed 20 July 2020

15.

Raoof N, Sharrack B, Pepper IM, Hickman SJ (2011) The incidence and prevalence of idiopathic intracranial hypertension in Sheffield, UK. Eur J Neurol 18(10):1266–1268PubMed

16.

Radhakrishnan K, Ahlskog JE, Cross SA, Kurland LT, O'Fallon WM (1993) Idiopathic intracranial hypertension (pseudotumor cerebri): descriptive epidemiology in Rochester, Minn, 1976–1990. Arch Neurol 50(1):78–80PubMed

17.

Durcan FJ, Corbett JJ, Wall M (1988) The incidence of pseudotumor cerebri: population studies in Iowa and Louisiana. Arch Neurol 45(8):875–877PubMed

18.

Craig JJ, Mulholland DA, Gibson JM (2001) Idiopathic intracranial hypertension; incidence, presenting features and outcome in Northern Ireland (1991–1995). Ulst Med J 70(1):31–35

19.

Kesler A, Stolovic N, Bluednikov Y, Shohat T (2014) The incidence of idiopathic intracranial hypertension in Israel from 2005 to 2007: results of a nationwide survey. Eur J Neurol 21(8):1055–1059PubMed

20.

Adderley NJ, Subramanian A, Nirantharakumar K, Yiangou A, Gokhale KM, Mollan SP, Sinclair AJ (2019) Association between idiopathic intracranial hypertension and risk of cardiovascular diseases in women in the United Kingdom. JAMA Neurol 76(9):1088–1098PubMedCentral

21.

Friesner D, Rosenman R, Lobb BM, Tanne E (2011) Idiopathic intracranial hypertension in the USA: the role of obesity in establishing prevalence and healthcare costs. Obes Rev 12(5):e372–e380PubMed

22.

Matthews YY, Dean F, Lim MJ, McLachlan K, Rigby AS, Solanki GA, White CP, Whitehouse WP, Kennedy CR (2017) Pseudotumor cerebri syndrome in childhood: incidence, clinical profile and risk factors in a national prospective population-based cohort study. Arch Dis Child 102(8):715–721PubMed

23.

Bruce BB, Kedar S, Van Stavern GP, Monaghan D, Acierno MD, Braswell RA, Preechawat P, Corbett JJ, Newman NJ, Biousse V (2009) Idiopathic intracranial hypertension in men. Neurology 72(4):304–309PubMedPubMedCentral

24.

Lun MP, Monuki ES, Lehtinen MK (2015) Development and functions of the choroid plexus–cerebrospinal fluid system. Nat Rev Neurosci 16(8):445–457PubMedPubMedCentral

25.

Fisone G, Snyder GL, Fryckstedt J, Caplan MJ, Aperia A, Greengard P (1995) Na⁺, K⁺-ATPase in the choroid plexus. Regulation by serotonin/protein kinase C pathway. J Biol Chem 270(6):2427–2430PubMed

26.

Bothwell SW, Janigro D, Patabendige A (2019) Cerebrospinal fluid dynamics and intracranial pressure elevation in neurological diseases. Fluids Barriers CNS 16(1):9–9PubMedPubMedCentral

27.

Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17(6):819–837PubMed

28.

Flint A, Raben A, Astrup A, Holst JJ (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Investig 101(3):515–520PubMed

29.

Carraro-Lacroix LR, Malnic G, Girardi AC (2009) Regulation of Na⁺/H⁺ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Ren Physiol 297(6):F1647–F1655

30.

Avisar I, Gaton DD, Dania H, Stiebel-Kalish H (2012) The prevalence of polycystic ovary syndrome in women with idiopathic intracranial hypertension. Scientifica (Cairo) 2012:708042

31.

Klein A, Stern N, Osher E, Kliper E, Kesler A (2013) Hyperandrogenism is associated with earlier age of onset of idiopathic intracranial hypertension in women. Curr Eye Res 38(9):972–976PubMed

32.

Hornby C, Mollan SP, Mitchell J, Markey KA, Yangou A, Wright BLC, O’Reilly MW, Sinclair AJ (2017) What do transgender patients teach us about idiopathic intracranial hypertension? Neuro-Ophthalmology 41(6):326–329PubMedPubMedCentral

33.

O'Reilly MW, Westgate CS, Hornby C, Botfield H, Taylor AE, Markey K, Mitchell JL, Scotton WJ, Mollan SP, Yiangou A et al (2019) A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics. JCI Insight 4(6):e125348PubMedCentral

34.

Sinclair AJ, Onyimba CU, Khosla P, Vijapurapu N, Tomlinson JW, Burdon MA, Stewart PM, Murray PI, Walker EA, Rauz S (2007) Corticosteroids, 11beta-hydroxysteroid dehydrogenase isozymes and the rabbit choroid plexus. J Neuroendocrinol 19(8):614–620PubMed

35.

Sinclair AJ, Walker EA, Burdon MA, van Beek AP, Kema IP, Hughes BA, Murray PI, Nightingale PG, Stewart PM, Rauz S et al (2010) Cerebrospinal fluid corticosteroid levels and cortisol metabolism in patients with idiopathic intracranial hypertension: a link between 11beta-HSD1 and intracranial pressure regulation? J Clin Endocrinol Metab 95(12):5348–5356PubMed

36.

Stimson RH, Walker BR (2013) The role and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Horm Mol Biol Clin Investig 15(2):37–48PubMed

37.

Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR (2005) Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 54(3):872–879PubMed

38.

Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS (2001) A transgenic model of visceral obesity and the metabolic syndrome. Science 294(5549):2166–2170PubMed

39.

Westgate C, Markey K, Ludwig C, Singhal R, Lavery G, Sinclair A (2018) Subcutaneous adipose tissue from patients with idiopathic intracranial hypertension exhibits metabolically distinctive characteristics. In: Society for endocrinology BES 2018. Glasgow, United Kingdom

40.

Boyle CD (2008) Recent advances in the discovery of 11beta-HSD1 inhibitors. Curr Opin Drug Discov Dev 11(4):495–511

41.

Hornby C, Mollan SP, Botfield H, OʼReilly MW, Sinclair AJ (2018) Metabolic concepts in idiopathic intracranial hypertension and their potential for therapeutic intervention. J Neuro-ophthalmol 38(4):522–530

42.

Dhungana S, Sharrack B, Woodroofe N (2009) Cytokines and chemokines in idiopathic intracranial hypertension. Headache 49(2):282–285PubMed

43.

Zanello SB, Tadigotla V, Hurley J, Skog J, Stevens B, Calvillo E, Bershad E (2018) Inflammatory gene expression signatures in idiopathic intracranial hypertension: possible implications in microgravity-induced ICP elevation. npj Microgravity 4(1):1PubMedPubMedCentral

44.

Edwards LJ, Sharrack B, Ismail A, Tench CR, Gran B, Dhungana S, Brettschneider J, Tumani H, Constantinescu CS (2013) Increased levels of interleukins 2 and 17 in the cerebrospinal fluid of patients with idiopathic intracranial hypertension. Am J Clin Exp Immunol 2(3):234–244PubMedPubMedCentral

45.

Alimajstorovic Z, Pascual-Baixauli E, Hawkes CA, Sharrack B, Loughlin AJ, Romero IA, Preston JE (2020) Cerebrospinal fluid dynamics modulation by diet and cytokines in rats. Fluids Barriers CNS 17(1):10PubMedPubMedCentral

46.

Sinclair AJ, Burdon MA, Nightingale PG, Ball AK, Good P, Matthews TD, Jacks A, Lawden M, Clarke CE, Stewart PM et al (2010) Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ 341:c2701PubMedPubMedCentral

47.

Manfield JH, Yu KK, Efthimiou E, Darzi A, Athanasiou T, Ashrafian H (2017) Bariatric surgery or non-surgical weight loss for idiopathic intracranial hypertension? A systematic review and comparison of meta-analyses. Obes Surg 27(2):513–521PubMed

48.

Ottridge R, Mollan SP, Botfield H, Frew E, Ives NJ, Matthews T, Mitchell J, Rick C, Singhal R, Woolley R et al (2017) Randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of idiopathic intracranial hypertension: the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT) protocol. BMJ Open 7(9):e017426PubMedPubMedCentral

49.

Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner JL, Schron EB, Kupersmith MJ (2014) Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA 311(16):1641–1651PubMed

50.

Uldall M, Botfield H, Jansen-Olesen I, Sinclair A, Jensen R (2017) Acetazolamide lowers intracranial pressure and modulates the cerebrospinal fluid secretion pathway in healthy rats. Neurosci Lett 645:33–39PubMed

51.

Smith SV, Friedman DI (2017) The idiopathic intracranial hypertension treatment trial: a review of the outcomes. Headache 57(8):1303–1310PubMed

52.

Ball AK, Howman A, Wheatley K, Burdon MA, Matthews T, Jacks AS, Lawden M, Sivaguru A, Furmston A, Howell S et al (2011) A randomised controlled trial of treatment for idiopathic intracranial hypertension. J Neurol 258(5):874–881PubMed

53.

Piper RJ, Kalyvas AV, Young AM, Hughes MA, Jamjoom AA, Fouyas IP (2015) Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev (8):Cd003434

54.

Scotton WJ, Botfield HF, Westgate CS, Mitchell JL, Yiangou A, Uldall MS, Jensen RH, Sinclair AJ (2019) Topiramate is more effective than acetazolamide at lowering intracranial pressure. Cephalalgia 39(2):209–218PubMed

55.

Alore PL, Jay WM, Macken MP (2006) Topiramate, pseudotumor cerebri, weight-loss and glaucoma: an ophthalmologic perspective. Semin Ophthalmol 21(1):15–17PubMed

56.

Celebisoy N, Gokcay F, Sirin H, Akyurekli O (2007) Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand 116(5):322–327PubMed

57.

Finsterer J, Foldy D, Fertl E (2006) Topiramate resolves headache from pseudotumor cerebri. J Pain Symptom Manag 32(5):401–402

58.

Mollan SP, Spitzer D, Nicholl DJ (2018) Raised intracranial pressure in those presenting with headache. BMJ 363:k3252PubMed

59.

Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38(1):1–211

60.

Friedman DI, Quiros PA, Subramanian PS, Mejico LJ, Gao S, McDermott M, Wall M (2017) Headache in idiopathic intracranial hypertension: findings from the idiopathic intracranial hypertension treatment trial. Headache 57(8):1195–1205PubMedPubMedCentral

61.

Friedman DI (2019) Headaches in idiopathic intracranial hypertension. J Neuro-ophthalmol 39(1):138

62.

Wakerley BR (2019) Medication-overuse headache. Pract Neurol 19(5):399–403PubMed

63.

Fridley J, Foroozan R, Sherman V, Brandt ML, Yoshor D (2011) Bariatric surgery for the treatment of idiopathic intracranial hypertension. J Neurosurg 114(1):34–39PubMed

64.

Duits FH, Martinez-Lage P, Paquet C, Engelborghs S, Lleo A, Hausner L, Molinuevo JL, Stomrud E, Farotti L, Ramakers I et al (2016) Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study. Alzheimers Dement 12(2):154–163PubMed

65.

Yiangou A, Mitchell J, Markey KA, Scotton W, Nightingale P, Botfield H, Ottridge R, Mollan SP, Sinclair AJ (2019) Therapeutic lumbar puncture for headache in idiopathic intracranial hypertension: minimal gain, is it worth the pain? Cephalalgia 39(2):245–253PubMed

66.

Penfield W, McNaughton F (1940) Dural headache and innervation of the dura mater. Arch Neurol Psychiatry 44(1):43–75

67.

Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J (1985) Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 62(1):131–136PubMed

68.

Iyengar S, Johnson KW, Ossipov MH, Aurora SK (2019) CGRP and the trigeminal system in migraine. Headache 59(5):659–681PubMedPubMedCentral

69.

Moulton EA, Burstein R, Tully S, Hargreaves R, Becerra L, Borsook D (2008) Interictal dysfunction of a brainstem descending modulatory center in migraine patients. PLoS ONE 3(11):e3799–e3799PubMedPubMedCentral

70.

Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R et al (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14(11):1091–1100PubMed

71.

Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B et al (2014) Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13(11):1100–1107PubMed

72.

Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS (2014) Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 13(9):885–892PubMed

73.

Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C (2016) Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther 356(1):223–231PubMed

74.

Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425–434PubMed

75.

Yuan H, Spare NM, Silberstein SD (2019) Targeting CGRP for the prevention of migraine and cluster headache: a narrative review. Headache 59(Suppl 2):20–32PubMed

76.

Moye LS, Pradhan AA (2017) From blast to bench: a translational mini-review of posttraumatic headache. J Neurosci Res 95(6):1347–1354PubMedPubMedCentral

77.

Navratilova E, Rau J, Oyarzo J, Tien J, Mackenzie K, Stratton J, Remeniuk B, Schwedt T, Anderson T, Dodick D, Porreca F (2019) CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice. Cephalalgia 39(14):1762–1775PubMed

78.

Friedman DI, Liu GT, Digre KB (2013) Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 81(13):1159–1165PubMed

79.

Fisayo A, Bruce BB, Newman NJ, Biousse V (2016) Overdiagnosis of idiopathic intracranial hypertension. Neurology 86(4):341–350PubMedPubMedCentral

80.

Digre KB, Nakamoto BK, Warner JE, Langeberg WJ, Baggaley SK, Katz BJ (2009) A comparison of idiopathic intracranial hypertension with and without papilledema. Headache 49(2):185–193PubMedPubMedCentral

81.

Mollan SP, Hornby C, Mitchell J, Sinclair AJ (2018) Evaluation and management of adult idiopathic intracranial hypertension. Pract Neurol 18(6):485–488PubMedPubMedCentral

82.

Hoffmann J, Mollan SP, Paemeleire K, Lampl C, Jensen RH, Sinclair AJ (2018) European headache federation guideline on idiopathic intracranial hypertension. J Headache Pain 19(1):93PubMedPubMedCentral

83.

Fard MA, Fakhree S, Abdi P, Hassanpoor N, Subramanian PS (2014) Quantification of peripapillary total retinal volume in pseudopapilledema and mild papilledema using spectral-domain optical coherence tomography. Am J Ophthalmol 158(1):136–143PubMed

84.

Skau M, Yri H, Sander B, Gerds TA, Milea D, Jensen R (2013) Diagnostic value of optical coherence tomography for intracranial pressure in idiopathic intracranial hypertension. Graefes Arch Clin Exp Ophthalmol 251(2):567–574PubMed

85.

Aojula A, Mollan SP, Horsburgh J, Yiangou A, Markey KA, Mitchell JL, Scotton WJ, Keane PA, Sinclair AJ (2018) Segmentation error in spectral domain optical coherence tomography measures of the retinal nerve fibre layer thickness in idiopathic intracranial hypertension. BMC Ophthalmol 17(1):257PubMedPubMedCentral

86.

Pollak L, Zohar E, Glovinsky Y, Huna-Baron R (2013) Reevaluation of presentation and course of idiopathic intracranial hypertension—a large cohort comprehensive study. Acta Neurol Scand 127(6):406–412PubMed

87.

Wong SH, Plant GT (2015) How to interpret visual fields. Pract Neurol 15(5):374PubMed

88.

Cello KE, Keltner JL, Johnson CA, Wall M (2016) Factors affecting visual field outcomes in the idiopathic intracranial hypertension treatment trial. J Neuroophthalmol 36(1):6–12PubMed

89.

Sinclair AJ, Kuruvath S, Sen D, Nightingale PG, Burdon MA, Flint G (2011) Is cerebrospinal fluid shunting in idiopathic intracranial hypertension worthwhile? A 10-year review. Cephalalgia 31(16):1627–1633PubMed

90.

Kalyvas AV, Hughes M, Koutsarnakis C, Moris D, Liakos F, Sakas DE, Stranjalis G, Fouyas I (2017) Efficacy, complications and cost of surgical interventions for idiopathic intracranial hypertension: a systematic review of the literature. Acta Neurochir (Wien) 159(1):33–49

91.

Gurney SP, Ramalingam S, Thomas A, Sinclair AJ, Mollan SP (2020) Exploring the current management idiopathic intracranial hypertension, and understanding the role of dural venous sinus stenting. Eye Brain 12:1–13PubMedPubMedCentral

92.

Saber H, Lewis W, Sadeghi M, Rajah G, Narayanan S (2018) Stent survival and stent-adjacent stenosis rates following venous sinus stenting for idiopathic intracranial hypertension: a systematic review and meta-analysis. Interv Neurol 7(6):490–500PubMedPubMedCentral

93.

Nicholson P, Brinjikji W, Radovanovic I, Hilditch CA, Tsang ACO, Krings T, Mendes Pereira V, Lenck S (2019) Venous sinus stenting for idiopathic intracranial hypertension: a systematic review and meta-analysis. J Neurointerv Surg 11(4):380–385PubMed

94.

Asif H, Craven CL, Siddiqui AH, Shah SN, Matloob SA, Thorne L, Robertson F, Watkins LD, Toma AK (2018) Idiopathic intracranial hypertension: 120-day clinical, radiological, and manometric outcomes after stent insertion into the dural venous sinus. J Neurosurg 129(3):723–731PubMed

95.

Satti SR, Leishangthem L, Chaudry MI (2015) Meta-analysis of CSF diversion procedures and dural venous sinus stenting in the setting of medically refractory idiopathic intracranial hypertension. AJNR Am J Neuroradiol 36(10):1899–1904PubMed

Title: Emerging themes in idiopathic intracranial hypertension
Authors: Olivia Grech
Susan P. Mollan
Benjamin R. Wakerley
Zerin Alimajstorovic
Gareth G. Lavery
Alexandra J. Sinclair
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Keywords: Obesity
Migraine
Obesity
Idiopathic Intracranial Hypertension
Intracranial Hypertension
Headache
Androgens
Published in: Journal of Neurology / Issue 12/2020
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-020-10090-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Emerging themes in idiopathic intracranial hypertension

Abstract

Purpose

Findings

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Findings

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2020

The neuro-otology of Susac syndrome

Izydor Fajersztajn-Krzemicki (1867–1935)

Prodromal Parkinson disease in patients with idiopathic hyposmia

Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity

COVID-19 reveals influence of physical activity on symptom severity in hereditary spastic paraplegia

Cell-based assays for the detection of MOG antibodies: a comparative study